Overview

Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis

Status:
Active, not recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

This trial is a phase II non-comparative study aimed to determine the feasibility and toxicity of the R-CHOP regimen in combination with intrathecal liposomal cytarabine and systemic intermediate-dose methotrexate followed by loco-regional radiotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

International Extranodal Lymphoma Study Group (IELSG)

Treatments:

Cyclophosphamide
Cytarabine
Doxorubicin
Methotrexate
Prednisolone
Rituximab
Vincristine